Influenza tetravalent vaccines in national immunization programs for Latin-American countries

• Autores: Macías Hernández, Alejandro E., Santos, Fortino Solórzano, Aguilar Velasco, Hugo M., Ávila Agüero, María L., Rubio, Fernando Bazzino, Junqueira Bellei, Nancy C., Bonvehí, Pablo E., Del Castillo, José Brea, Leguizamón, Héctor Castro, Allan Santos Domingues, Carla M., García García, María D.L., Trujillo, Darío Londoño, Lópe, Pío López, De León Rosales, Samuel Ponce, Cervantes Powell, Patricia G., Suárez Ognio, Luis A.N., Ruiz-Palacios y Santos, Guillermo M.
• Formato: artículo
• Fecha de Publicación: 2020
• Institución: Universidad Peruana de Ciencias Aplicadas
• Repositorio: UPC-Institucional
• Lenguaje: español
• OAI Identifier: oai:repositorioacademico.upc.edu.pe:10757/655697
• Enlace del recurso: http://hdl.handle.net/10757/655697
• Nivel de acceso: acceso abierto
• Materia: Influenza b; Latin America; Tetravalent influenza vaccine; Article; Cost effectiveness analysis; Hospitalization; Human; Influenza A; Influenza B; Influenza vaccination

Since 2012-2013 influenza season, World Health Organization (who) recommends the formulation of tetravalent vaccines. Globally, many countries already use tetravalent vaccines in their national immunization programs, while in Latin America only a small number. Two Influenza b lineages co-circulate, their epidemiological behavior is unpredictable. On average they represent 22.6% of influenza cases and more than 50% in predominant seasons. The lack of concordance between recommended and circulating strains was 25 and 32% in the 2010-2017 and 2000-2013 seasons, respectively. There are no clinical differences between influenza A and B. It occurs more frequently from five to 19 years of age. Influenza b has a higher proportion of attributable deaths than influenza a (1.1 vs. 0.4%), or 2.65 (95% ci 1.18-5.94). A greater number of hospitalizations when the strains mismatch (46.3 vs. 28.5%; p <.0001). Different evaluations have demonstrated its cost effectiveness. The compilation of this information supports the use of quadrivalent vaccines in Latin American countries.